A strategy for developing novel drugs for the treatment of schizophrenia.
نویسنده
چکیده
Antipsychotic drugs currently in use have been developed as antidopaminergic agents; that is, normalization of psychotic symptoms occurs through a reduction in dopaminergic activity, usually by blockade of postsynaptic dopamine receptors. Based on this current understanding of the mechanism of action of antipsychotic drugs, it is suggested that one physiological role of the dopaminergic system is to down-regulate in the face of biological or psychological insult, as a means of maintaining mental stability. An attempt to develop new drugs to improve the efficiency of this down-regulative system as an alternative to conventional drugs that block dopamine receptors is proposed.
منابع مشابه
Effects of Bromocriptine on Negative Symptoms of Schizophrenia: A Double Blind Clinical Trial
Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...
متن کاملEvaluation of the Pharmacotherapeutic Pattern for Treating Schizophrenia in Bangladesh
Background: Studies of the pharmacotherapeutic pattern on schizophrenic patients are few clinical therapy is one of the bases for the assessment of the treatment of Schizophrenia. Objectives: This study aimed to analyze the demographics of these patients along with current trends of drug prescribing practice in Bangladesh. Methods: This survey was conducted over 6 months at the National Insti...
متن کامل5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic...
متن کاملEfficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial
Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...
متن کاملNanotechnology application in cancer treatment
Chemotherapy has been the main known treatment for cancer diseases. However, its achievement rate remains low, mainly because of the restricted accessibility of drugs to the tumor tissue, their painful toxicity, and development of multi-drug resistance. In recent years, either better understanding of tumor biology or development of the ever-growing field of nanotechnology has proposed new treat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Schizophrenia bulletin
دوره 9 4 شماره
صفحات -
تاریخ انتشار 1983